Biopharmaceutical Biz Closes $259M Upsized Funding Round
South San Francisco, California-based clinical-stage biopharmaceutical company Alumis Inc. on Wednesday announced that it closed its upsized Series C funding round after securing $259 million from venture capital investors....To view the full article, register now.
Already a subscriber? Click here to view full article